Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors

Telisotuzumab vedotin (formerly ABBV‐399) is an antibody‐drug conjugate targeting c‐Met–overexpressing tumor cells, irrespective of MET gene amplification status. Safety, pharmacokinetics, and preliminary efficacy of telisotuzumab vedotin were evaluated outside of Japan. This phase 1 open‐label stud...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Fujiwara, Yutaka, Kenmotsu, Hirotsugu, Yamamoto, Noboru, Shimizu, Toshio, Yonemori, Kan, Ocampo, Christopher, Parikh, Apurvasena, Okubo, Sumiko, Fukasawa, Kazuteru, Murakami, Haruyasu
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7982615/
https://ncbi.nlm.nih.gov/pubmed/33675179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3815
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados